The Great Reversal: American Cancer Society Now Recommends Routine PSA Screening for All Men

In a dramatic paradigm shift, the American Cancer Society (ACS) published on Thursday, November 12, a completely rewritten guideline for the early detection of prostate cancer — and the difference from the previous version is enormous. Since 2010, the organization had adopted a "shared decision-making" stance, leaving it to the patient and physician to decide whether the prostate-specific antigen (PSA) blood test was worth performing. Now, the recommendation is direct: all men should be tested.

For men at average risk, the new guideline establishes PSA tests every two years between ages 50 and 69. For Black men and those with a strong family history of prostate cancer, the annual test should begin at age 45. The decision to continue screening between ages 70 and 74 becomes individual, based on overall health and life expectancy. Above age 75, screening is not recommended.

Why the change?

The answer lies in two fronts that have radically changed the prostate cancer landscape over the past 16 years. First, the quality of PSA tests themselves has improved significantly — the standardized methods in use today are far more reliable than those available at the time of the previous guideline. Second, clinical management strategies have evolved to dramatically reduce the harms associated with screening: unnecessary biopsies have decreased thanks to more precise biomarkers, and treatments for low-risk tumors — such as active surveillance — have become established practices.

"The changes reflect stronger evidence of the benefits of PSA-based screening combined with the increasing use of management strategies that can reduce harms, such as unnecessary biopsies and treatment," the ACS explained in its official statement.

The impact is particularly severe in vulnerable populations. Black men in the United States present a 67% higher incidence rate and nearly double the mortality rate compared to White men — a disparity the ACS identifies as a priority. "By making a direct recommendation for men to engage in screening and advocating for earlier and more frequent screening for Black men, our aim is also to help reduce prostate cancer disparities," said Dr. William Dahut, chief scientific officer at the organization.

What changes in practice?

The difference between the 2010 guideline and the 2026 update can be summed up in one word: universality. The previous guide made no universal recommendations. It said: men from age 50 should talk with their doctors about the risks and benefits before deciding. It was a "if you want to, think about it" approach.

The new guideline is much more assertive. It not only recommends screening but establishes clear frequencies: every two years for average risk, annually for high risk. And for the first time, PSA thresholds that warrant attention have been quantified: 3.0 ng/mL or higher for men between 45 and 69, and 6.5 ng/mL or higher for men between 70 and 74. When exceeded, the patient should undergo a new test between two weeks and three months later.

But the real innovation is not just in "when" and "for whom" — it's in "how." The new guideline emphasizes that before initiating screening, physicians must ensure that patients understand not only the potential benefits but also the limitations and potential harms. It's an intentional paradox: universally recommend the test, but universally inform about its risks.

The epidemiological context

The numbers justify the change in posture. Prostate cancer is the second leading cause of cancer death among men in the United States, with estimates of 333,000 diagnoses and 36,320 deaths just for this year. The disease is so prevalent that, statistically, one in four men will receive a diagnosis during their lifetime.

The American Cancer Society commissioned a modeling study to evaluate the cost-benefit tradeoffs of different screening strategies, integrating mortality, survival, and quality-of-life data. The results indicate that a well-calibrated screening scheme — with defined intervals and a focus on higher-risk men — can significantly reduce deaths without generating excessive numbers of unnecessary procedures.

The question that remains is whether this 180-degree reversal puts us at the beginning of another dramatic shift in 16 years — or whether what has truly changed is the knowledge that now allows us to extract maximum value from a cheap, accessible test without the costs that once made it problematic.

Sources: American Cancer Society, STAT News, American Hospital Association

✓ Independent sources cross-checked and verified before publishing